CLASS I Device recall · Reported 18 Sep 2013 · FDA Enforcement Report

Microscan rapID/S panels NC3.12 recalled

Siemens Healthcare Diagnostics is recalling Microscan rapID/S panels NC3.12, distributed nationwide in the US. The recall was initiated on 21 Aug 2013 and the FDA has classified it as Class I.

Check your package

Lot, batch or date codesInternal Number - J1025-312; Catalog Number - 10444793
Quantity recalled57,600 panels in total

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-2128-2013
FDA event ID
66058
Recalling firm
Siemens Healthcare Diagnostics, West Sacramento, CA
Classification
Class I
Status
Terminated
Recall initiated
21 Aug 2013
FDA classified
11 Sep 2013
Reported
18 Sep 2013
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Other Reasons

Timeline

21 Aug 2013Recall initiated by company
11 Sep 2013Classified by FDA+21 days
18 Sep 2013Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Confirmed increase in false susceptible and false intermediate misreads for Imipenem and/or meropenum on Synergies plus Negative and rap ID/S plus Negative panels read on Walk Away System.

Product as listed by the FDA

Microscan rapID/S panels NC3.12 Sold in Japan only. Product Usage: MicroScan¿ Synergies plus¿ Panels & MicroScan¿ Rapids plus (Negative) - For use in determining quantitative and/or qualitative antimicrobial agent susceptibility and/or identification for gram-negative bacteria.

Where it was distributed

Worldwide Distribution - USA Nationwide in the states of: AK, SC, IA, MO GA, WI, TX, KS, CA, IL, CO, AZ, SD, IN, MD, FL, MN and the countries of:Japan, France, Algeria, Germany, Austria, Romania, Russian Federation, South Africa, Kazakhstan, Belgium, Great Britain, Turkey, Spain, Italy, Saudi Arabia, Qutar, Poland, Iraq, Unite Arab Emrites, Algeria, Oman, Greece, Portugal, and Ireland.

Nationwide AlaskaArizonaCaliforniaColoradoFloridaGeorgiaIowaIllinoisIndianaKansasMarylandMinnesotaMissouriSouth CarolinaSouth DakotaTexasWisconsin

Questions about this recall

Why was it recalled?

Confirmed increase in false susceptible and false intermediate misreads for Imipenem and/or meropenum on Synergies plus Negative and rap ID/S plus Negative panels read on Walk Away System.

Which lots are affected?

Internal Number - J1025-312; Catalog Number - 10444793

Where was it sold?

Worldwide Distribution - USA Nationwide in the states of: AK, SC, IA, MO GA, WI, TX, KS, CA, IL, CO, AZ, SD, IN, MD, FL, MN and the countries of:Japan, France, Algeria, Germany, Austria, Romania, Russian Federation, South Africa, Kazakhstan, Belgium, Great Britain, Turkey, Spain, Italy, Saudi Arabia, Qutar, Poland, Iraq, Unite Arab Emrites, Algeria, Oman, Greece, Portugal, and Ireland.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class I mean?

Class I is the most serious FDA recall category: there is a reasonable probability that using the product will cause serious health consequences or death.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other products in this recall event

10 other products · FDA event 66058

This product is part of a recall event; the main page for the event is Microscan Synergies Plus Negative Urine Combo recalled.

More recalls from Siemens Healthcare Diagnostics

All 694

Other Other Medical Devices recalls

All 13,778